Teva, Sun Pharma to pay $2.15 bn to settle Pfizer patent suit for acid-reflux drug
Fp Archives • 12 years ago This is the first instance of generic drugmakers paying damages for marketing a copy of an existing drug for which patents have yet to expire - known as an 'at-risk' launch.
